{"title":"Metabolite Profiling and In silico Studies to Elucidate the Antiinflammatory\nProperties of Pterocarpus Milbreadii","authors":"P. Aba, Ismaila Onuche Odugbo","doi":"10.2174/0115734080277468231129075038","DOIUrl":null,"url":null,"abstract":"\n\nPterocarpus milbreadii (PM), called Rosewood in English, is a leafy vegetable\nused in preparing soup and has also proven medicinal.\n\n\n\nThis study aimed to evaluate the most abundant compound in the ethylacetate fraction of\nPM using Gas Chromatography-mass Spectrometry (GC-MS) and docking it against cyclooxygenase\nisoenzymes.\n\n\n\nThe PM leaves were extracted with ethyl acetate using the cold maceration method. The\nextract was subjected to GC-MS assay. The spectra obtained were matched with NIST 17. AutoDock\nVina was used to perform the molecular docking of the most abundant compound of PM and cyclooxygenase.\nCelecoxib was used as the standard ligand.\n\n\n\nThe results of the study revealed that the ethyl acetate leaf extract of PM contained different\nphytochemicals, with hexadecenoic acid being the most abundant, with an intensity count of 9.5 x108\nCPS. Docking of hexadecenoic acid and Celecoxib with COX-2 yielded binding energies of -6.7 and\n-7.7 kcal/mol, respectively, while with COX-1, the binding energies of -6.3 and -9.8 kcal/mol were\nrespectively recorded. Hexadecenoic acid interacted with both COX-1 and COX-2 largely via Van\nder waals and pi-Alkyl bonds. Celecoxib made conventional hydrogen, carbon-hydrogen, halogen,\npi-sigma, pi-alkyl interactions with the cyclooxygenase isoenzymes.\n\n\n\nIt was concluded that hexadecenoic acid was the predominant phytochemical in the\nethylacetate leaf extract of PM. The hexadecanoic acid ligand produced a better inhibitory effect on\nCOX-2 compared to COX-1.\n","PeriodicalId":35405,"journal":{"name":"Current Enzyme Inhibition","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Enzyme Inhibition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115734080277468231129075038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Pterocarpus milbreadii (PM), called Rosewood in English, is a leafy vegetable
used in preparing soup and has also proven medicinal.
This study aimed to evaluate the most abundant compound in the ethylacetate fraction of
PM using Gas Chromatography-mass Spectrometry (GC-MS) and docking it against cyclooxygenase
isoenzymes.
The PM leaves were extracted with ethyl acetate using the cold maceration method. The
extract was subjected to GC-MS assay. The spectra obtained were matched with NIST 17. AutoDock
Vina was used to perform the molecular docking of the most abundant compound of PM and cyclooxygenase.
Celecoxib was used as the standard ligand.
The results of the study revealed that the ethyl acetate leaf extract of PM contained different
phytochemicals, with hexadecenoic acid being the most abundant, with an intensity count of 9.5 x108
CPS. Docking of hexadecenoic acid and Celecoxib with COX-2 yielded binding energies of -6.7 and
-7.7 kcal/mol, respectively, while with COX-1, the binding energies of -6.3 and -9.8 kcal/mol were
respectively recorded. Hexadecenoic acid interacted with both COX-1 and COX-2 largely via Van
der waals and pi-Alkyl bonds. Celecoxib made conventional hydrogen, carbon-hydrogen, halogen,
pi-sigma, pi-alkyl interactions with the cyclooxygenase isoenzymes.
It was concluded that hexadecenoic acid was the predominant phytochemical in the
ethylacetate leaf extract of PM. The hexadecanoic acid ligand produced a better inhibitory effect on
COX-2 compared to COX-1.
期刊介绍:
Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.